Evidence map›Paper›PMID 41563184›Full record

ArticleJACC. Case reports2026

Chemotherapy-Induced Cardiomyopathy in Pregnancy: A Multidisciplinary Approach.

Cristina Nunez Pellot, Allison Akers, Shantelle Bartra, Ashley Young, Xiangkun Cao, Mary Ashley Cain, Daniela Crousillat

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Cristina Nunez PellotDivision of Cardiovascular Sciences, Department of Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA; Tampa General Hospital (TGH) Heart and Vascular Institute, Tampa, Florida, USA. Electronic address: cristinaedil@usf.edu.
Allison AkersDivision of Maternal Fetal Medicine, Department of Gynecology & Obstetrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Shantelle BartraLee Health Heart Institute, Fort Myers, Florida, USA.
Ashley YoungTampa General Hospital (TGH) Heart and Vascular Institute, Tampa, Florida, USA.
Xiangkun CaoLee Health Heart Institute, Fort Myers, Florida, USA.
Mary Ashley CainDivision of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA; Department of Obstetrics & Gynecology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
Daniela CrousillatDivision of Cardiovascular Sciences, Department of Medicine, University of South Florida Morsani College of Medicine, Tampa, Florida, USA; Tampa General Hospital (TGH) Heart and Vascular Institute, Tampa, Florida, USA; Department of Obstetrics & Gynecology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPatients with cancer and chemotherapy-induced cardiomyopathy are at increased risk for adverse maternal and fetal outcomes in pregnancy. We present the multidisciplinary cardio-obstetrics management of anthracycline-associated cardiomyopathy in pregnancy in the context of breast cancer therapy. CASE SUMMARY: A 38-year-old woman gravida 4 para 3 with a history of BRCA1 mutation was diagnosed with triple negative stage IIIB breast cancer at 10 weeks' gestation. She developed new-onset cardiomyopathy presumed to be chemotherapy-induced cardiac dysfunction after initiation of treatment with doxorubicin and cyclophosphamide. Her chemotherapy was transitioned to alternative regimen, and her symptomatic heart failure and ventricular arrhythmias were managed with beta-blockers, diuretics, and antiarrhythmic therapy. Collaborative management led to uncomplicated delivery with positive maternal and fetal outcomes. DISCUSSION: Chemotherapy-related cardiac dysfunction during pregnancy demands vigilant cardiac surveillance, tailored therapy during pregnancy, and precise labor and delivery planning by a multidisciplinary team to optimize maternal and fetal outcomes.

Indexed as

cancer in pregnancycardiomyopathy in pregnancycardio-obstetricschemotherapy-induced cardiomyopathymultidisciplinary teamventricular arrhythmias in pregnancy

Identifiers

PMID41563184
PMCPMC13080905

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.